Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease

NCT00831467 is registered in ClinicalTrials.gov with CureVac as lead sponsor.

NCT NCT00831467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00831467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease
Lead sponsor
CureVac
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2009
Completion date
September 30, 2013
Enrollment
48 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hormonal refractory prostate cancer